Abcc3, also known as MRP3, is a member of the ABCC subfamily of ATP - Binding Cassette (ABC) transporters. These transporters play a crucial role in the transport of endo - and xenobiotics, and Abcc3 specifically can confer resistance to natural, synthetic drugs and their conjugated metabolites [3]. It is involved in processes like bile acid secretion and may influence lysosomal homeostasis [2,4].

In hepatocellular carcinoma (HCC), BRG1 was found to directly bind to the Abcc3 promoter to activate its transcription, promoting HCC carcinogenesis. Depletion of BRG1 in BRG1high HCC cells decelerated proliferation and migration, effects that were rescued by Abcc3 over - expression [2]. In pancreatic ductal adenocarcinoma (PDAC), Abcc3 is overexpressed, and its disruption by genetic knockdown reduces pancreatic cancer cell growth in vitro and in vivo, through inhibition of STAT3 and HIF1α signalling pathways [5]. In colorectal cancer, down - regulation of Abcc3 activates MAPK signalling through the accumulation of deoxycholic acid [4].

In conclusion, Abcc3 is an important transporter gene involved in drug resistance and carcinogenesis in multiple cancer types. Studies using gene - knockdown or knockout models in these cancers have revealed its role in promoting cancer cell growth, proliferation, and migration, suggesting it could be a potential therapeutic target for improving cancer treatment [1,2,5].